research Obesity and the Skin: Skin Physiology and Skin Manifestations of Obesity
Obesity affects skin health, causing conditions like acanthosis nigricans and may require different treatment approaches.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Nonhuman Primate Dermatology: A Literature Review
The document concludes that veterinary dermatologists need more experience and a better approach to treating skin diseases in nonhuman primates.
research Newly Emerging Type B Insulin Resistance During Treatment With Eculizumab for AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: Fatal Outcome
A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
research First Use of Thymus Transplantation Therapy for FOXN1 Deficiency (Nude/SCID): A Report of 2 Cases
Thymus transplantation successfully restored immune function in infants with FOXN1 deficiency.
research Safety of Treatment Options for Spondyloarthritis: A Narrative Review
Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.
research New Treatments for Rheumatoid Arthritis
New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
research Subject Index
The document lists various dermatology topics, treatments, and diagnostic methods.
research Methotrexate Dose Has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial
Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
research Cutaneous Manifestations and Considerations in COVID-19 Pandemic: A Systematic Review
COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research Review Article: Dermatological Complications of Immunosuppressive and Anti-TNF Therapy in Inflammatory Bowel Disease
Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series
Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
research Baricitinib: From Rheumatoid Arthritis to COVID-19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
research Multiple Sclerosis Disease-Modifying Therapies: Adverse Effect Surveillance and Management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research Cutaneous Manifestations in Biologically Treated Inflammatory Bowel Disease Patients: A Narrative Review
Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.
research Treatments for Alopecia Areata: A Network Meta-Analysis
The analysis aims to identify the most effective and safest treatments for alopecia areata.
research Ethnobotany, Phytochemistry, and Pharmacology of the Mediterranean Dwarf Palm (Chamaerops Humilis L.)
The Mediterranean dwarf palm has medicinal, nutritional, and craft uses, but more research is needed.
research Alopecia Areata: Treatment Options and Efficacy
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Symptom Management in Inflammatory Bowel Disease
Effective symptom management in IBD improves quality of life and prevents complications.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Hair and Diabetes: Implications and Case Studies
Hair conditions can be linked to diabetes and affect psychological health.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Treatments for Alopecia Areata: A Network Meta-Analysis
The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research Procedure of Tattooing
Tattooing guidelines focus on safety, hygiene, and following rules.
research JAK Inhibitors and Alopecia Areata
JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
research Circulatory Changes in Alopecia
The document suggests that the traditional understanding of hair growth cycles and alopecia may be inaccurate and that blood supply plays a significant role in hair growth and loss.
research A Novel Approach to Manage Skin Toxicity Caused by Therapeutic Agents Targeting Epidermal Growth Factor Receptor
New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.